Cladribine for highly active relapsing multiple sclerosis

This article summarises its dosing and monitoring requirements, efficacy in the CLARITY trial and place in therapy.

Source: Prescriber - February 22, 2018 Category: Primary Care Authors: Steve Chaplin Tags: New Product Source Type: research